On 28 June, 2019, tumor marker product: Cancer Antigen 242 diagnostic kit (Chemiluminescent Microparticle Immunoassay) achieved medical device registration certificate.
About product:
This kit is used to quantitatively detect the cancer antigen 242 (CA242) in human serum. It is mainly used to dynamically monitor patients with malignant tumors to assist to determine disease progression or treatment effect. However, it cannot be used as an early diagnosis or diagnostic basis for malignant tumors and tumor screening in the general population.
To know about product:
CA242 is a sialylated carbohydrate antigen, mainly found in malignant cells of the pancreas and colon, and a small amount of CA242 is also contained in normal human tissues. When a malignant tumor occurs in the digestive tract, the concentration of CA242 in the serum will increase. Therefore, CA242 has a higher specificity than other tumor markers and has a very low false positive rate in benign diseases. The detection of CA242 content in serum can be used for the monitoring of pancreatic cancer and colorectal cancer. It also has a certain positive detection rate for lung cancer and breast cancer. It is of great significance for the efficacy judgment and follow-up observation after the treatment of malignant tumors.
